Somalogic
More Proteins, Less Profit: Why SomaLogic's Multiplexing Advantages Haven't Led to Greater Success
Premium
Researchers and industry observers indicated that past business decisions are the main driver of the company's performance, but the new CEO aims to right the ship.
SomaLogic Raises Full-Year 2023 Guidance on 14 Percent Q3 Core Revenue Growth
The proteomics firm beat Wall Street estimates on the top and bottom lines, though total revenues were down 47 percent due to a royalty payment last year.
New Products Posted to GenomeWeb: Pacific Biosciences, Illumina, Tempus, New England Biolabs, More
New products and services posted to GenomeWeb for the week of Oct. 30, 2023
The firms' merger agreement, filed with the US Securities and Exchange Commission, contradicts previous messaging on layoffs at Standard BioTools.
Standard BioTools, SomaLogic to Merge
The companies will do business under the name Standard BioTools, which was adopted by Fluidigm in 2022.